Literature DB >> 21110380

Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.

Jeremy L Yap1, Shilpa Worlikar, Alexander D MacKerell, Paul Shapiro, Steven Fletcher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21110380      PMCID： PMC3477473          DOI： 10.1002/cmdc.201000354

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  49 in total

1.  Changes in protein conformational mobility upon activation of extracellular regulated protein kinase-2 as detected by hydrogen exchange.

Authors:  A N Hoofnagle; K A Resing; E J Goldsmith; N G Ahn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

Review 2.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.

Authors:  G Pearson; F Robinson; T Beers Gibson; B E Xu; M Karandikar; K Berman; M H Cobb
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

3.  Pharmacologic inhibitors of MKK1 and MKK2.

Authors:  N G Ahn; T S Nahreini; N S Tolwinski; K A Resing
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

4.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

5.  Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.

Authors:  N Zhang; B Wu; D Powell; A Wissner; M B Floyd; E D Kovacs; L Toral-Barza; C Kohler
Journal:  Bioorg Med Chem Lett       Date:  2000-12-18       Impact factor: 2.823

Review 6.  Discovery of a novel Raf kinase inhibitor.

Authors:  J F Lyons; S Wilhelm; B Hibner; G Bollag
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

7.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.

Authors:  M Milella; S M Kornblau; Z Estrov; B Z Carter; H Lapillonne; D Harris; M Konopleva; S Zhao; E Estey; M Andreeff
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

8.  Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.

Authors:  Victoria Emuss; Mathew Garnett; Clive Mason; Richard Marais
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

9.  Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK.

Authors:  A Zhao; S H Lee; M Mojena; R G Jenkins; D R Patrick; H E Huber; M A Goetz; O D Hensens; D L Zink; D Vilella; A W Dombrowski; R B Lingham; L Huang
Journal:  J Antibiot (Tokyo)       Date:  1999-12       Impact factor: 2.649

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962
View more
  19 in total

Review 1.  Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases.

Authors:  Michael J Schnieders; Tamer S Kaoud; Chunli Yan; Kevin N Dalby; Pengyu Ren
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  The nuclear translocation of ERK1/2 as an anticancer target.

Authors:  Alexander Plotnikov; Karen Flores; Galia Maik-Rachline; Eldar Zehorai; Einat Kapri-Pardes; Denise A Berti; Tamar Hanoch; Michal J Besser; Rony Seger
Journal:  Nat Commun       Date:  2015-03-30       Impact factor: 14.919

3.  Molecular modeling and structure-based drug discovery approach reveals protein kinases as off-targets for novel anticancer drug RH1.

Authors:  Pramodkumar P Gupta; Virupaksha A Bastikar; Dalius Kuciauskas; Shanker Lal Kothari; Jonas Cicenas; Mindaugas Valius
Journal:  Med Oncol       Date:  2017-09-06       Impact factor: 3.064

4.  Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.

Authors:  Kwan-Young Jung; Ramin Samadani; Jay Chauhan; Kerrick Nevels; Jeremy L Yap; Jun Zhang; Shilpa Worlikar; Maryanna E Lanning; Lijia Chen; Mary Ensey; Sagar Shukla; Rosene Salmo; Geoffrey Heinzl; Caryn Gordon; Troy Dukes; Alexander D MacKerell; Paul Shapiro; Steven Fletcher
Journal:  Org Biomol Chem       Date:  2013-06-14       Impact factor: 3.876

Review 5.  Recent progress in pancreatic cancer.

Authors:  Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban
Journal:  CA Cancer J Clin       Date:  2013-07-15       Impact factor: 508.702

6.  Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf.

Authors:  Ramin Samadani; Jun Zhang; Amanda Brophy; Taiji Oashi; U Deva Priyakumar; E Prabhu Raman; Franz J St John; Kwan-Young Jung; Steven Fletcher; Edwin Pozharski; Alexander D MacKerell; Paul Shapiro
Journal:  Biochem J       Date:  2015-05-01       Impact factor: 3.857

7.  MicroRNA-21 mediates high phosphate-induced endothelial cell apoptosis.

Authors:  Zhaoyu Li; Szymon Wiernek; Cam Patterson; Huanchen Wang; Guoxian Qi; Xuming Dai
Journal:  Am J Physiol Cell Physiol       Date:  2018-09-26       Impact factor: 4.249

8.  Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.

Authors:  S Liu; J Zha; M Lei
Journal:  Clin Transl Oncol       Date:  2017-08-01       Impact factor: 3.405

Review 9.  Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.

Authors:  Lauren Dennison; Aditya A Mohan; Mark Yarchoan
Journal:  Curr Oncol Rep       Date:  2021-02-06       Impact factor: 5.945

10.  A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.

Authors:  Colin Weekes; Albert Lockhart; Patricia LoRusso; Elaine Murray; Erica Park; Mike Tagen; Jatinder Singh; Indrani Sarkar; Lars Mueller; Hatem Dokainish; Geoffrey Shapiro; Howard Burris
Journal:  Oncologist       Date:  2020-05-28       Impact factor: 5.837
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.